Zinger Key Points
- Novo Nordisk’s drug Ozempic helps patients with type-2 diabetes manage blood sugar levels and weight.
- Kimmel poked fun at the Academy’s response, or lack thereof, to Smith’s slap last year.
- Get New Picks of the Market's Top Stocks
During the 95th Academy Awards ceremony hosted by Jimmy Kimmel on Sunday night, he poked fun at the rumor that Hollywood actors are using Ozempic, Novo Nordisk’s NVO diabetes drug, to lose weight.
What Happened: Kimmel touched on a number of hot topics, including poking fun at Hollywood stars that are collectively rumored to be using new weight-loss drugs like Ozempic to maintain their physiques.
“Everybody looks so great,” Kimmel said. “I can’t help but wonder if Ozempic is right for me.”
See Also: Looking To Shed Some Pounds? WeightWatchers To Offer Weight-Loss Drugs Like Ozempic
Ozempic is a drug designed by Novo Nordisk to help patients with type-2 diabetes manage blood sugar levels and weight to help prevent severe events like heart attacks and strokes.
But the drug has been proven to help people lose weight regardless of if they have diabetes or not. Because of this, many people seek out Ozempic for the “off-label” use of weight loss.
The Slap Lives On: Kimmel also joked about Will Smith slapping Chris Rock during last year’s Oscar’s ceremony, saying the Academy had instituted new policies to help prevent any slaps at this year’s event.
Kimmel said that anyone who gets upset as a joke and wishes to rush to the stage would have to go through Adonis Creed, Michael B. Jordan’s character in the "Rocky" movie spinoff series.
Kimmel also seemed to poke fun at the Academy’s response, or lack thereof, to Smith’s slap last year.
“The academy has a crisis team in place, and if anything unpredictable or violent happens during the ceremony, just do what you did last year, Kimmel said. “Nothing. Just sit there and do absolutely nothing. Maybe even give the assailant a hug.”
Read Next: Netflix Vs Disney: Who Won The Battle Of Oscars 2023?
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.